Skip to content

Randomized double-blind controlled prospective study on the efficacy of Yizhi Decoction in the treatment of Alzheimer's disease

Randomized double-blind controlled prospective study on the efficacy of Yizhi Decoction in the treatment of Alzheimer's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005157
Enrollment
Unknown
Registered
2021-08-09
Start date
2021-09-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

Sponsors

Wuhan University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Residents of the community, those who participate in the community elderly physical examination; 2. The age is 65-85 years old; 3. Expected survival period > 1 year; 4. No tumor, congenital or acquired immunodeficiency disease, congestive heart failure, angina pectoris, myocardial infarction, uncontrolled hypertension or arrhythmia and other serious heart diseases, active hepatitis, liver cirrhosis and other serious liver diseases , Any serious kidney disease such as glomerulonephritis, nephrotic syndrome, uremia, etc., without chronic diarrhea; 5. Blood routine and electrocardiogram were in the normal range when entering the group, the upper limit of liver and kidney function measurements was <=1.5 times the normal value, blood pressure systolic blood pressure <160mmHg, diastolic blood pressure <100mmHg; 6. Patients with mild to moderate AD, patients with mild cognitive impairment; 7. Elderly patients with depression; 8. Informed consent of patients or their guardians.

Exclusion criteria

Exclusion criteria: 1. Patients with suicidal tendencies, that is, those with a score of >= 2 on the third item of the Hamilton Depression Scale; 2. Those with a history of drug allergy; 3. Alcoholism and/or psychoactive substances, drug abusers and dependents (including sleeping pills); 4. Those who do not use the prescribed medication, cannot judge the efficacy or incomplete data, etc., which affect the judgment of efficacy and safety; 5. Those who are unable to understand the contents of the scale due to insufficient awareness, language barriers, intelligence and education level (below primary school education); 6. Visual or hearing impairment prevents the test or assessor.

Design outcomes

Primary

MeasureTime frame
Biochemical detection index;Psychoaffective assessment;General cognitive tests;Proteomic detection;Cognitive domain test;Imaging Characteristics;Genetic detection;

Secondary

MeasureTime frame
Anthropometric indexes;Family histories;Demographics and socioeconomic position;TCM Constitution Classification;Coating on the tongue;Behavior characteristics;Previous histories;Activities of daily living and basic activities of daily living;

Countries

China

Contacts

Public ContactZeng Yan

Wuhan University of Science and Technology

yanzeng11@foxmail.com+86 15972921169

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026